Skip to toolbar

Activity

  • importx posted an update 7 months, 3 weeks ago

    Liposomal doxorubicin is an anthracycline antitumor drug in clinical applications. It has a long duration of action and can directly affect tumor sites.While the liposome doxorubicin kills tumor cells, it also causes obvious adverse reactions, such as bone marrow suppression, heart damage, etc., which limited its applications.There is currently no effective treatment for malignant tumors, but the deterioration of the condition can be controlled by taking drugs. Clinically, cancer treatment drugs can be divided into first-line drugs, second-line drugs, and so on. Liposomal doxorubicin was once a first-line treatment for ovarian cancer and is a very common anthracycline antitumor drug. The main component is doxorubicin hydrochloride, which is an injection.The role of liposome doxorubicinSince the discovery of liposomes by Bangham in 1965, Gregoriadis and Rymen first reported the use of liposomes as drug carriers in 1971. Liposomes began to be effective carriers of anthracycline antitumor drugs in the late 1970s. Liposomes are bi-molecular vesicles similar to the structure of biological membranes. They are vesicles with single or multiple bilayer phospholipid membranes. The main component is phospholipids. Phospholipid molecules containing phosphate groups have a strong polarity (hydrophilic), the hydrocarbon chain is non-polar (hydrophobic).The advantage of liposome doxorubicin1. It can be biodegraded by human body and has low immunogenicity.2. Both water-soluble and fat-soluble drugs can be embedded and carried, the drug is slowly released, and the drug effect lasts for a long time.3. Through endocytosis and fusion, liposomes can directly deliver drugs into cells, avoiding the use of high concentrations of free drugs to reduce adverse reactions.4. The capillary wall of normal tissues is intact and most of the liposomes cannot penetrate. While the permeability of the capillaries of tumor growth sites increases, which increases the accumulation of liposome doxorubicin. It is used for tumor sites and increases the therapeutic effect. After liposome doxorubicin enters the human circulation, it is mainly engulfed by leukocytes, monocytes and macrophages in the reticuloendothelial system (RES), which has special significance for the treatment of RES tumors. The application of early liposomal doxorubicin was limited due to poor stability, easy leakage of drugs, short shelf life, poor tissue targeting, and rapid clearance by RES. The liposomes (peatedliposomaldoxorubicin, PLD, or “stealth” liposomes, stealthliposome, whose trade name is Caelyx) are now coated on the surface with a macromolecular substance, polyethylene glycol, which improve the hydrophilicity of its surface. Moreover, Caelyx derivatives can prevent the adsorption of plasma proteins, attached on the surface of liposomes, reduce the phagocytosis and absorption of RES, evade the interception of the immune system, and prolong the circulation time of the drug in the body.In addition to ovarian cancer, liposome doxorubicin also has good therapeutic effect on breast cancer, liver cancer, and lung cancer. Liposomal doxorubicin can also treat a wide range of skin and mucosal visceral diseases and AIDS-related Kaposi’s sarcoma. Liposomal doxorubicin is a systemic chemotherapeutic drug.